A study involving 346 patients with hepatocellular carcinoma and microvascular invasion demonstrated that adjuvant transcatheter arterial chemoembolization (TACE) combined with lenvatinib significantly improves overall survival and recurrence-free survival compared to no adjuvant therapy. Group one, which received both treatments, showed superior outcomes (overall survival HR 0.321, recurrence-free survival HR 0.319), whereas groups receiving either treatment alone did not show significant differences in survival benefits. This combination therapy is recommended for enhancing post-hepatectomy recovery.
Journal Article by Liang L, Xu ZD (…) Huang DS et 11 al. in Asian J Surg
Copyright © 2024 Asian Surgical Association and Taiwan Society of Coloproctology. Published by Elsevier B.V. All rights reserved.